64
August 29, 2025 — Leads & Copy — Swedish Orphan Biovitrum AB (Sobi®) reports a total of 357,412,837 shares as of August 29, 2025, comprising 356,000,049 common shares and 1,412,788 C-shares, resulting in 356,141,327.8 total votes. The increase stems from issuing 1,412,788 class C shares to fulfill long-term incentive program commitments. The company holds 11,343,74 common shares.
Sobi is a global biopharma company focused on breakthrough innovations for people with rare diseases, employing approximately 1,900 individuals across Europe, North America, the Middle East, Asia, and Australia. In 2024, the company’s revenue reached SEK 26 billion. Sobi’s share (STO:SOBI) is listed on Nasdaq Stockholm.
Gerard Tobin
Head of Investor Relations
